Institutional Investor Highlights Leadership in European Equity Research

European Equity
Exane BNP Paribas maintains its position as number 1 research provider for Developed Europe from Institutional Investor Research, for 5 years running.

Like many sectors, the Equity Research industry has experienced significant changes due to the Covid-19 pandemic; from the rapid adaptation in the way firms build and manage client relationships virtually, to an intensified competition in the quality and quantity of written research.


Against this backdrop, the latest 2021 European Institutional Investor Research (II Research) survey has named Exane BNP Paribas as the Number 1 Research Provider for Developed Europe, for the 5th year running. This achievement reinforces Exane BNP Paribas’ solid position as Europe’s leading Cash Equities franchise, reflecting its deep understanding of the European markets which is widely recognised by clients who consistently ranked the business as the go-to provider.


Other key achievements include:


  • Number 1 in Industry Research – including 16 number 1 rankings out of 30 sectors


  • Number 1 for Ranked Analysts – with 44 top 3 or runner-up positions


  • Specialist Sales ranked top 3 positions in 24 categories (out of a maximum of 31)


The highly competitive annual survey is based on feedback from the buy-side, so the rankings demonstrate the strength of Exane BNP Paribas’ client relationships and the consistent performance of this business, not only through this extremely challenging time, but over several years.


These results follow the recent announcement of BNP Paribas’ acquisition of Exane, underpinning the bank’s ambition to build a leading global equities house.



About Institutional Investor Research


II Research surveys are the leading provider of market sentiment in the financial industry, offering highly-respected proprietary benchmark research and rankings, with independent feedback on the sell-side and corporate performance.


More information on the survey results can be found on the Institutional Investor article.

Leave a Reply

Your email address will not be published. Required fields are marked *